Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, Bioavailability, and Food Effect of AZD5462 in Healthy Participants
NCT05512806Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of AZD5462 in heart failure (HF) (6 arms), sponsored by AstraZeneca. Primary endpoints: Area under plasma concentration time curve from zero to infinity, Area under the plasma concentration-curve from time zero to last quantifiable concentration and 1 more. Started Aug 2022; status: completed.
02
Drugs
AZD5462
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT05512806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05512806.